DK2771350T3 - Topk-peptider og vacciner, der indbefatter disse - Google Patents

Topk-peptider og vacciner, der indbefatter disse Download PDF

Info

Publication number
DK2771350T3
DK2771350T3 DK12844519.4T DK12844519T DK2771350T3 DK 2771350 T3 DK2771350 T3 DK 2771350T3 DK 12844519 T DK12844519 T DK 12844519T DK 2771350 T3 DK2771350 T3 DK 2771350T3
Authority
DK
Denmark
Prior art keywords
peptide
topk
seq
peptides
present
Prior art date
Application number
DK12844519.4T
Other languages
English (en)
Inventor
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Sachiko Yoshimura
Tomohisa Watanabe
Gaku Nakayama
Original Assignee
Onco Therapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Therapy Science Inc filed Critical Onco Therapy Science Inc
Application granted granted Critical
Publication of DK2771350T3 publication Critical patent/DK2771350T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/12—Dual-specificity kinases (2.7.12)
    • C12Y207/12002—Mitogen-activated protein kinase kinase (2.7.12.2), i.e. MAPKK or MEK1 or MEK2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Claims (19)

1. Isoleret peptid på mindre end 15 aminosyrer valgt fra gruppen, der består af (a) og (b) nedenfor: (a) et isoleret peptid, der har cytotoksisk T-lymfocyt (CTL)- inducerbarhed og omfatter en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 42, 45, 47, 50, 51, 53, 54, 62, 63, 64, 66, 71, 72 og 76, og (b) et isoleret peptid, der omfatter en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 42, 45, 47, 50, 51, 53, 54, 62, 63, 64, 66, 71, 72 og 76, hvor 1 eller 2 aminosyre(r) er substitueret, indsat og/eller tilføjet, hvor peptidet har CTL-inducerbarhed.
2. Isoleret peptid ifølge krav 1, hvor peptidet har én eller begge af følgende egenskaber: (a) den anden aminosyre fra N-terminalen af en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 42, 45, 47, 50, 51, 53, 54, 62, 63, 64, 66, 71, 72 og 76, er substitueret med en aminosyre valgt fra gruppen, der består af leucin og methionin; og (b) den C-terminale aminosyre af en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 42, 45, 47, 50, 51, 53, 54, 62, 63, 64, 66, 71, 72 og 76, er substitueret med en aminosyre valgt fra gruppen, der består af valin og leucin.
3. Isoleret peptid ifølge krav 1 eller 2, hvor peptidet er et nonapeptid eller et dekapeptid.
4. Isoleret peptid, der består af en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 42, 45, 47, 50, 51, 53, 54, 62, 63, 64, 66, 71, 72 og 76.
5. Isoleret polynukleotid, der koder for det isolerede peptid ifølge et hvilket som helst af kravene 1 til 4.
6. Sammensætning til inducering af en CTL, hvor sammensætningen omfatter et eller flere peptid(er) ifølge et hvilket som helst af kravene 1 til 4 eller et eller flere polynukleotid(er) ifølge krav 5.
7. Farmaceutisk sammensætning, der omfatter: (a) et eller flere peptid(er) ifølge et hvilket som helst af kravene 1 til 4, (b) et eller flere polynukleotid(er) ifølge krav 5, (c) en eller flere APC(er), der præsenterer et kompleks af peptidet ifølge et hvilket som helst af kravene 1 til 4 og et HLA-antigen på overfladen; (d) et eller flere exosom(er), der præsenterer et kompleks af peptidet ifølge et hvilket som helst af kravene 1 til 4 og et HLA-antigen på overfladen; eller (e) en eller flere CTL(er), der kan genkende en celle, der præsenterer et kompleks af peptidet ifølge et hvilket som helst af kravene 1 til 4 og et HLA-antigen på overfladen, i kombination med et farmaceutisk acceptabelt bæremiddel, hvor den farmaceutiske sammensætning er formuleret til behandling og/eller profylakse af cancer, forebyggelse af et postoperativt recidiv deraf og/eller induktion af et immunrespons mod cancer.
8. Farmaceutisk sammensætning ifølge krav 7, hvor den farmaceutiske sammensætning er formuleret til administration til en person, hvis HLA-antigen er HLA-A2.
9. In vitro-fremgangsmåde til inducering af en antigenpræsenterende celle (APC) med CTL-inducerbarhed, hvilken fremgangsmåde omfatter et trin valgt fra gruppen, der består af: (a) etablering af kontakt mellem en APC og peptidet ifølge et hvilket som helst af kravene 1 til 4 in vitro og (b) indførelse af et polynukleotid, der koder for peptidet ifølge et hvilket som helst af kravene 1 til 4, i en APC.
10. In vitro-f remgangsmåde til inducering af en CTL, hvilken fremgangsmåde omfatter et trin valgt fra gruppen, der består af: (a) samdyrkning af en CD8-positiv T-celle og en APC, der på dens overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge et hvilket som helst af kravene 1 til 4, (b) samdyrkning af en CD8-positiv T-celle og et exosom, der på dets overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge et hvilket som helst af kravene 1 til 4, og (c) indførelse i en CD8-positiv T-celle af et eller flere polynukleotid(er) , der koder for et eller flere T-cellereceptor (TCR)-subunitpolypeptid(er), hvor TCR'en, der dannes af TCR-subunitpolypeptiderne, er i stand til at binde til et kompleks af et HLA-antigen og peptidet ifølge et hvilket som helst af kravene 1 til 4, på en celleoveflade.
11. Isoleret APC, der på dens overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge et hvilket som helst af kravene 1 til 4.
12. APC ifølge krav 11, der induceres ved hjælp af fremgangsmåden ifølge krav 9.
13. Isoleret CTL, der er målrettet peptidet ifølge et hvilket som helst af kravene 1 til 4.
14. CTL ifølge krav 13, der induceres ved hjælp af fremgangsmåden ifølge krav 10.
15. Sammensætning til anvendelse til inducering af et immunrespons mod cancer hos en person, der har brug for det, hvor sammensætningen omfatter peptidet ifølge et hvilket som helst af kravene 1 til 4 eller et polynukleotid, der koder for peptidet.
16. Vektor, der omfatter en nukleotidsekvens, der koder for peptidet ifølge et hvilket som helst af kravene 1 til 4.
17. Værtscelle, der er transformeret eller transficeret med vektoren ifølge krav 16.
18. Diagnostisk kit, der omfatter peptidet ifølge et hvilket som helst af kravene 1 til 4 eller polynukleotidet ifølge krav 5.
19. Fremgangsmåde til screening for et peptid, som har evnen til at inducere en CTL, der har specifik cytotoksisk aktivitet mod en celle, der præsenterer et fragment afledt fra TOPK, hvilken fremgangsmåde omfatter trinene: (i) tilvejebringelse af en kandidatsekvens, der består af en aminosyresekvens, der er modificeret ved substitution, indsættelse og/eller tilføjelse af en eller to aminosyrerester i forhold til en oprindelig aminosyresekvens, hvor den oprindelige aminosyresekvens er valgt fra gruppen, der består af SEQ ID NO: 42, 45, 47, 50, 51, 53, 54, 62, 63, 64, 66, 71, 72 og 76; (ii) udvælgelse af en kandidatsekvens, der ikke har væsentlig signifikant homologi med peptiderne, der er afledt fra et hvilket som helst andet kendt humant genprodukt end TOPK; (iii) etablering af kontakt mellem et peptid, der består af kandidatsekvensen, der er valgt i trin (ii) , og en antigenpræsenterende celle; (iv) etablering af kontakt mellem den antigenpræsenterende celle i trin (iii) og en CD8-positiv T-celle; og (v) identificering af et peptid, for hvilket CTL-inducerbarheden er den samme som eller højere end for et peptid, der består af den oprindelige aminosyresekvens.
DK12844519.4T 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse DK2771350T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552817P 2011-10-28 2011-10-28
PCT/JP2012/006853 WO2013061594A1 (en) 2011-10-28 2012-10-25 Topk peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
DK2771350T3 true DK2771350T3 (da) 2018-04-30

Family

ID=48167445

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17198358.8T DK3296317T3 (da) 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse
DK12844519.4T DK2771350T3 (da) 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17198358.8T DK3296317T3 (da) 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse

Country Status (19)

Country Link
US (2) US9427461B2 (da)
EP (2) EP3296317B1 (da)
JP (2) JP6124149B2 (da)
KR (2) KR102127211B1 (da)
CN (2) CN107759661B (da)
AU (2) AU2012329502B2 (da)
BR (2) BR112014009176B1 (da)
CA (2) CA3122778A1 (da)
DK (2) DK3296317T3 (da)
ES (2) ES2665576T3 (da)
IL (2) IL231583B (da)
IN (1) IN2014CN03922A (da)
MX (2) MX355759B (da)
PH (1) PH12014500720A1 (da)
RU (1) RU2633503C2 (da)
SG (3) SG10201913173SA (da)
TW (2) TWI617582B (da)
UA (1) UA114298C2 (da)
WO (1) WO2013061594A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10277755B2 (en) * 2016-02-29 2019-04-30 Kyocera Document Solutions Inc. Electronic device and marker processing method
EP4649954A3 (en) 2017-01-25 2025-12-17 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
EP3765071A4 (en) * 2018-03-12 2022-05-25 The Children's Hospital of Philadelphia METHODS AND COMPOSITIONS FOR USE OF TUMOR AUTOGENS IN ADOPTIVE IMMUNOTHERAPY
WO2022066973A1 (en) * 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
US20240024438A1 (en) * 2020-11-19 2024-01-25 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class peptides
CN117957012A (zh) * 2021-07-19 2024-04-30 得克萨斯州大学系统董事会 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
JP2004510442A (ja) * 2000-10-03 2004-04-08 グラクソ　グループ　リミテッド 腫瘍マーカーおよび使用方法
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
EP1856278A2 (en) 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
ES2584247T3 (es) 2005-07-27 2016-09-26 Oncotherapy Science, Inc. Gen TOM34 relacionado con el cáncer de colon
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
WO2008018642A2 (en) * 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
EA018457B1 (ru) * 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
ES2679127T3 (es) * 2007-12-05 2018-08-22 International Institute Of Cancer Immunology, Inc. Composición vacunal contra el cáncer
EP2356230A4 (en) 2008-08-27 2012-04-04 Oncotherapy Science Inc LGF / GPSM2 GENERAL WITH CANCER
CN102439147A (zh) 2009-03-04 2012-05-02 肿瘤疗法科学股份有限公司 Vangl1肽及包含它们的疫苗
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer

Also Published As

Publication number Publication date
JP6349560B2 (ja) 2018-07-04
JP6124149B2 (ja) 2017-05-10
HK1201542A1 (en) 2015-09-04
KR102127211B1 (ko) 2020-06-29
UA114298C2 (uk) 2017-05-25
PH12014500720A1 (en) 2014-06-30
CN107759661A (zh) 2018-03-06
BR122021015246B1 (pt) 2023-03-28
RU2014121502A (ru) 2015-12-10
BR112014009176B1 (pt) 2022-08-30
DK3296317T3 (da) 2020-02-24
EP3296317A1 (en) 2018-03-21
HK1251236A1 (en) 2019-01-25
US9849166B2 (en) 2017-12-26
CN104066746A (zh) 2014-09-24
AU2017200530A1 (en) 2017-02-23
CN107759661B (zh) 2021-03-23
TWI617582B (zh) 2018-03-11
JP2017093442A (ja) 2017-06-01
MX355759B (es) 2018-04-27
EP2771350A1 (en) 2014-09-03
KR20190107156A (ko) 2019-09-18
IL231583B (en) 2019-02-28
EP3296317B1 (en) 2019-12-11
TW201716429A (zh) 2017-05-16
CN104066746B (zh) 2017-12-05
ES2665576T3 (es) 2018-04-26
US20160310586A1 (en) 2016-10-27
EP2771350A4 (en) 2015-07-15
BR112014009176A2 (pt) 2020-10-27
IL231583A0 (en) 2014-05-28
SG2014012363A (en) 2014-09-26
ES2773699T3 (es) 2020-07-14
IL245924B (en) 2019-03-31
KR20140085565A (ko) 2014-07-07
TWI681973B (zh) 2020-01-11
CA2852633A1 (en) 2013-05-02
SG10201913173SA (en) 2020-03-30
AU2012329502A1 (en) 2014-05-29
AU2017200530B2 (en) 2018-08-09
CA3122778A1 (en) 2013-05-02
TW201333044A (zh) 2013-08-16
JP2014533095A (ja) 2014-12-11
AU2012329502B2 (en) 2016-11-24
EP2771350B1 (en) 2018-01-10
CA2852633C (en) 2021-08-03
RU2633503C2 (ru) 2017-10-12
IL245924A0 (en) 2016-07-31
MX2014004875A (es) 2014-09-22
KR102020491B1 (ko) 2019-09-10
US20140255437A1 (en) 2014-09-11
WO2013061594A1 (en) 2013-05-02
US9427461B2 (en) 2016-08-30
MX380003B (es) 2025-03-11
SG10201608552WA (en) 2016-12-29
IN2014CN03922A (da) 2015-09-04

Similar Documents

Publication Publication Date Title
AU2017200530B2 (en) TOPK peptides and vaccines including the same
WO2012169200A1 (en) Sema5b peptides and vaccines including the same
AU2013317194B2 (en) UBE2T peptides and vaccines containing the same
WO2011125334A1 (en) Cdca5 peptides and vaccines including the same
EP2742133B1 (en) Mphosph1 peptides and vaccines including the same
DK2646546T3 (da) Tomm34-peptider og vacciner, der indeholder disse
DK2553096T3 (da) Ect2-peptider og vacciner, der indbefatter disse
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
WO2011074236A1 (en) Tmem22 peptides and vaccines including the same
WO2014087626A1 (en) Sema5b peptides and vaccines containing the same
WO2012053200A1 (en) C18orf54 peptides and vaccines including the same
WO2012053206A1 (en) Wdhd1 peptides and vaccines including the same
HK1251236B (en) Topk peptides and vaccines including the same
HK1201542B (en) Topk peptides and vaccines including the same
HK1194435B (en) Mphosph1 peptides and vaccines including the same
HK1194435A (en) Mphosph1 peptides and vaccines including the same